Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold shares of the company's common stock. According to a recent SEC filing, Roberts sold 1,457 shares on January 31 at an average price ...

The company has a long list of other collaborators, including AstraZeneca, Neurocrine Biosciences, Biohaven Pharma, GSK, Roche/Genentech, Takeda, Sanofi, and AbbVie.

Sosei Heptares, meanwhile, is partnering with Neurocrine Biosciences on another GPCR-targeting drug, muscarinic M4 agonist NBI-1117568, which has reached the phase 2 testing stage as a ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price target is Yen4,800.00.

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Neurocrine (NBIX – Research Report) on January 31 and set a price target of ...

After leading Japan’s largest drugmaker for 11 years, Takeda CEO Christophe Weber plans to step down in June of 2026. He will ...

Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product ...